Taro Pharmaceutical Industries : Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or “the Company”) today announced the launch of a new specialty generic, deferiprone, an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of […]

Click here to view original web page at www.marketscreener.com